EUVIMEDAtrasti EUVIMED
Randomisierte kontrollierte StudieOpen access

A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.

Cecilia L Bergeria iD, Hongjun Tan iD, Denis Antoine iD, Elise M Weerts iD, Andrew S Huhn iD, J Gregory Hobelmann, Kelly E Dunn

Experimental and Clinical Psychopharmacology · 2023-02 · 31 (1) · 194-203

DOI: 10.1037/pha0000550 ↗

At a glance

Randomisierte kontrollierte Studie in Experimental and Clinical Psychopharmacology, 2023-02. Written by Cecilia L Bergeria and 6 co-authors. Institution: Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine. Major MEDLINE topics: Buprenorphine, Opioid-Related Disorders, Substance Withdrawal Syndrome. Cited 5 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, Dalio Philanthropies, Canopy Growth Corporation.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Successful management of opioid withdrawal improves long-term treatment outcomes and reduces opioid use-related morbidity and mortality. Mechanistically supported pharmacotherapeutic approaches are needed to effectively manage acute and protracted opioid withdrawal. Buspirone is a D2 antagonist and 5-HT1a agonist that may decrease opioid withdrawal. Individuals (n = 15) admitted to a residential treatment center for opioid use disorder (OUD) were enrolled into a double-blind randomized clinical trial to assess the efficacy and acceptability of buspirone (45 mg/day) as an adjunctive medication to buprenorphine-assisted, supervised opioid withdrawal. Participants completed daily questionnaires which consisted of the Subjective Opiate Withdrawal Scale (SOWS) and a consensus sleep diary, which assessed total sleep time, time to sleep onset, and sleep quality. Total SOWS scores, individual opioid withdrawal symptoms and sleep outcomes were assessed between treatment groups (Placebo and Buspirone) and over time in a repeated measures linear mixed model. Total SOWS scores significantly decreased across study phases for both groups but decreased to a greater extent among individuals assigned to buspirone during both the first and second week of stable buspirone. Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Participants also reported significant increases in sleep duration and significant decreases in latency to sleep onset. This study provides further support that buspirone can help mitigate opioid withdrawal during a supervised opioid taper. Buspirone may confer unique benefits during protracted withdrawal periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).

Subjects

MeSH terms (MEDLINE)

BuprenorphineOpioid-Related DisordersSubstance Withdrawal SyndromeHumansAnalgesics, OpioidBuspironeNarcotic AntagonistsNarcoticsAnalgesicsDouble-Blind MethodTreatment Outcome

Substances

BuprenorphineAnalgesics, OpioidBuspironeNarcotic AntagonistsNarcoticsAnalgesics

Authors and institutions

  • Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.

ORCID profiles: Cecilia L Bergeria, Hongjun Tan, Denis Antoine, Elise M Weerts, Andrew S Huhn

Funding

  • NIDA NIH HHS
  • Dalio Philanthropies
  • Canopy Growth Corporation
  • Ashley Addiction Treatment

Cite

APA

Bergeria, C. L., Tan, H., Antoine, D., Weerts, E. M., Huhn, A. S., Hobelmann, J. G., & Dunn, K. E. (2023). A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal. Experimental and Clinical Psychopharmacology, 31(1), 194-203. https://doi.org/10.1037/pha0000550

Vancouver

Bergeria CL, Tan H, Antoine D, Weerts EM, Huhn AS, Hobelmann JG, et al. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal. Experimental and Clinical Psychopharmacology. 2023;31(1):194-203. doi:10.1037/pha0000550

BibTeX
@article{Bergeria2023,
  author = {Bergeria, Cecilia L and Tan, Hongjun and Antoine, Denis and Weerts, Elise M and Huhn, Andrew S and Hobelmann, J Gregory and Dunn, Kelly E},
  title = {A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal},
  journal = {Experimental and Clinical Psychopharmacology},
  year = {2023},
  volume = {31},
  number = {1},
  pages = {194--203},
  doi = {10.1037/pha0000550}
}
Start for free →